EUCTR2019-001462-15-PL进行中（未招募）1 期
A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial) - ID
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subject had a previous allogeneic HSCT as indicated for non-malignant (including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies, and bone marrow failure syndromes) or haematological malignant disease, irrespective of human leukocyte antigen match
- •- Subject has been clinically diagnosed with Grade II to IV aGvHD at the Screening Visit.
- •- Subject has experienced failure of previous first line aGvHD treatment (ie, SR aGvHD), defined as:
- •a. aGvHD progression within 3 to 5 days of therapy onset with = 2 mg/kg/day of prednisone equivalent or
- •b. failure to improve within 5 to 7 days of treatment initiation with = 2 mg/kg/day of prednisone equivalent or
- •c. incomplete response after > 28 days of immunosuppressive treatment including at least 5 days with = 2 mg/kg/day of prednisone equivalent.
- •-Male or female subject who is = 12 years of age and = 15 kg at the Screening Visit.
- •-Subject has an estimated life expectancy > 28 days at the Screening Visit (compliance to be re-confirmed at the Baseline Visit).
- •-Subject, if female and of childbearing potential, agrees to use a highly effective contraceptive measure starting at the Screening Visit and continuing throughout the entire trial period. The definition of women of childbearing potential (WOCBP) and a complete list of highly effective contraceptive measures .are included in an appendix to the protocol.
- •-Subject, if a fertile male, agrees to sexual abstinence or to use a condom during sexual activity with their female partner of childbearing potential or pregnant partner. Additionally, if their partner is a WOCBP, then their partner has to use an additional highly effective contraceptive method during sexual activity starting at the Screening Visit and continuing throughout the entire trial period. For theThe definition of fertile men and a complete list of highly effective contraceptive measures are included in an appendix to the protocol.
- •-Subject or parent(s) / legal guardian(s) have read, understood, and signed the informed consent form (and informed assent form, if applicable) according to national regulations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Subject has overt relapse or progression or persistence of the underlying disease at the Screening Visit.
- •- Subject has received the last HSCT for a solid tumour disease.
- •- Subject has GvHD overlap syndrome at the Screening Visit.
- •- Subject has received systemic first-line treatment for aGvHD other than steroids and a prophylaxis with other than calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, anti-thymocyte globulin (ATG), mycophenolate mofetil (MMF), methotrexate (MTX), and / or cyclophosphamide before the Screening Visit (compliance to be re-confirmed at the Baseline Visit).
- •Please Note: In vitro or in vivo graft manipulation to prevent GvHD (eg, T-cell depletion) during HSCT is permitted. Restart of initial prophylaxis with calcineurin inhibitors or mTOR inhibitors after aGvHD onset is permitted.
- •- Subject has a known pregnancy (as confirmed by a positive pregnancy test at the Screening Visit) and or is breastfeeding at the Screening Visit.
- •- Subject has received treatment with any other investigational agent within 30 days or 5 half-lives (whichever is longer) before the Screening Visit (compliance to be confirmed for the period between the Screening Visit and the Baseline Visit at the Baseline Visit).
研究者
相似试验
进行中（未招募）
1 期
An experimental study in adults and adolescents who underwent stem cell transplantation and developed a sustained acute graft rejection after steroid treatment; to test the safety, tolerability and the effects of treatment with mesenchymal stromal cells MC0518Steroid refractory Acute Graft versus host DiseaseMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2019-001462-15-FRmedac Gesellschaft für klinische Spezialpräparate mbH210
进行中（未招募）
1 期
An experimental study in adults and adolescents who underwent stem cell transplantation and developed a sustained acute graft rejection after steroid treatment; to test the safety, tolerability and the effects of treatment with mesenchymal stromal cells MC0518Steroid refractory Acute Graft versus host DiseaseMedDRA version: 27.0Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2019-001462-15-DEmedac Gesellschaft für klinische Spezialpräparate mbH210
招募中
1 期
An experimental study in adults and adolescents who underwent stem cell transplantation and developed a sustained acute graft rejection after steroid treatment; to test the safety, tolerability and the effects of treatment with mesenchymal stromal cells MC0518Steroid refractory Acute Graft versus host DiseaseMedDRA version: 20.1Level: PTClassification code: 10066260Term: Acute graft versus host disease Class: 100000004870CTIS2023-505737-26-00Medac Gesellschaft fuer klinische Spezialprapaerate mbH210
进行中（未招募）
不适用
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis SubjectsPulmonary pseudomonas aeruginosa infections in patients with cystic fibrosisClassification code 10011762EUCTR2005-003772-37-DEovartis Pharma Services AG500
进行中（未招募）
1 期
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects - TIP003EUCTR2005-003772-37-IEovartis Pharma Services AG500